301 related articles for article (PubMed ID: 21852787)
1. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
van de Donk NW; Kamps S; Mutis T; Lokhorst HM
Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
3. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
4. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
6. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
10. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of multiple myeloma.
Huang YW; Vitetta ES
Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Hayashi T; Hideshima T; Akiyama M; Podar K; Yasui H; Raje N; Kumar S; Chauhan D; Treon SP; Richardson P; Anderson KC
Br J Haematol; 2005 Jan; 128(2):192-203. PubMed ID: 15638853
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
16. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
[TBL] [Abstract][Full Text] [Related]
17. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
18. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of multiple myeloma.
Richardson PG; Lonial S; Jakubowiak AJ; Harousseau JL; Anderson KC
Br J Haematol; 2011 Sep; 154(6):745-54. PubMed ID: 21777223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
